Inivata and Agendia Sign Agreement for Commercialization of RaDaR® MRD Liquid Biopsy Assay in Breast Cancer
Inivata and Agendia Sign Agreement for Commercialization of RaDaR® MRD Liquid Biopsy Assay in Breast Read More
Pathologic Complete Response (pCR) Rates According to MammaPrint and BluePrint Results are Consistent Among Pre- and Post-Menopausal Patients
Authors Pat Whitworth, James V Pellicane, Jr., Paul Read More
Landmark Long-Term Data from EORTC’s MINDACT Study Published in The Lancet Oncology
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – March 12, 2021 Read More
Data Presented at the Miami Breast Cancer Conference Show MammaPrint® and BluePrint® Accurately Predict Pathologic Complete Response Rate Regardless of Age
Results support use of Agendia’s genomic tests to better tailor Read More
Agendia to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Agendia to Participate in the BTIG MedTech, Digital Health, Life Read More
Agendia to Participate in the 39th Annual J.P. Morgan Healthcare Conference
IRVINE, Calif.--(BUSINESS WIRE)--Agendia, Inc., a world leader in precision oncology Read More
Racial disparities within Basal-type breast cancer: clinical and molecular features of African American and Caucasian obese patients
PUBLICATION: SABCS 2020 AUTHORS: Dipali Sharma, Lisa E. Blumencranz, Heather Read More
Molecular profiles and clinical-pathological features of Asian early-stage breast cancer patients
PUBLICATION: SABCS 2020 AUTHORS: Margaret Chen, Ava Kwong, Carolyn Hendricks, Read More
Comparing MammaPrint and BluePrint results between core needle biopsy and surgical resection breast cancer specimens
PUBLICATION: SABCS 2020 AUTHORS: Joseph McKelley, Jennifer Wei, Brian Hoxeng, Read More
MammaPrint and BluePrint as prognostic indicators for elderly patients with early-stage breast cancer
PUBLICATION: SABCS 2020 AUTHORS: Peter W. Blumencranz, Mehran Habibi, Lisa Read More
